KARE Biosciences

KARE BiosciencesKARE BiosciencesKARE Biosciences

KARE Biosciences

KARE BiosciencesKARE BiosciencesKARE Biosciences
  • Home
  • About Us
    • Pipeline
    • Our Science
    • Our Publications
    • Our Patents
  • News
    • Presentations
    • Our Blog
  • Our Team
  • Contact
  • More
    • Home
    • About Us
      • Pipeline
      • Our Science
      • Our Publications
      • Our Patents
    • News
      • Presentations
      • Our Blog
    • Our Team
    • Contact
  • Home
  • About Us
    • Pipeline
    • Our Science
    • Our Publications
    • Our Patents
  • News
    • Presentations
    • Our Blog
  • Our Team
  • Contact

Ramatroban (KAR101) as a potential treatment for silicosis

Targeting thromboxane/TP and prostaglandin D2/DP2 signaling with KAR101 may reduce lung inflammation, fibrosis and cardiopulmonary dysfunction in silicosis.

Ramatroban in the Silicosis mouse model

PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis

PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis

PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis

Multi-omics study of silicosis reveals the potential therapeutic targets PGD2 and TXA2

PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis

PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis

Pang and colleagues tested ramatroban in silicosis model constructed by a single intratracheal instillation of 8mg silica in 40µL PBS in male C57BL/6J mice of 8-10 weeks old. Pang et al, Theranostics, 2021, doi: 10.7150/thno.47627

PGD2 and TXA2 were significantly increased in silicosis mouse lungs

PGD2 and TxA2 synthase are significantly upregulated in the lungs of patients with silicosis

PGD2 and TXA2 were significantly increased in silicosis mouse lungs

Ramatroban reduces lung fibrosis induced by silica

Ramatroban reduces inflammation and improves pulmonary function

PGD2 and TXA2 were significantly increased in silicosis mouse lungs

Ramatroban reduces inflammation and improves pulmonary function

Ramatroban reduces inflammation and improves pulmonary function

Ramatroban reduces inflammation and improves pulmonary function

Ra=ramatroban; Crs=compliance of the respiratory system

Ramatroban improves cardiopulmonary function

Ramatroban reduces inflammation and improves pulmonary function

Ramatroban reduces inflammation and improves pulmonary function

RVSP=right ventricular systolic pressure; RVHI= right ventricular hypertrophy index

Ramatroban in Silicosis Presentation

    Development of Ramatroban in Silicosis

    Ramatroban has been used for the treatment of allergic rhinitis in Japan for over 20 years, and therefore, has an excellent safety profile. Given the efficacy of ramatroban in reducing fibrosis, inflammation and cardiopulmonary dysfunction in the silicosis mouse model, we are looking to conduct clinical trials of ramatroban in patients with silicosis. 

    Contact Us

    Looking for global partners to develop ramatroban (KAR101) in silicosis

    Message us on WhatsApp

    KARE Biosciences

    Email: karebiosciences@outlook.com Phone: +1 (562) 412-6259

    Send Us Message

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Copyright © 2023 KARE Biosciences - All Rights Reserved.


    Powered by GoDaddy